<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00736775</url>
  </required_header>
  <id_info>
    <org_study_id>ABE4427g</org_study_id>
    <nct_id>NCT00736775</nct_id>
  </id_info>
  <brief_title>A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease</brief_title>
  <official_title>A Phase I, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous MABT5102A Administered in a Single-Dose, Dose-Escalation Stage Followed by a Multidose, Parallel-Treatment Stage in Patients With Mild to Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is a Phase I, multicenter, randomized, double-blind, placebo-controlled study that will
      be conducted in the United States and consists of a single ascending-dose stage followed by a
      multidose, parallel-treatment stage. This study will be conducted in approximately 50 adult
      patients between 50-85 years old who have mild to moderate Alzheimer's disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of single and multiple doses of MABT5102A</measure>
    <time_frame>Through study completion or early study discontinuation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MABT5102A after single and multiple doses</measure>
    <time_frame>Through study completion or early study discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of MABT5102A after single and multiple doses</measure>
    <time_frame>Through study completion or early study discontinuation</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">56</enrollment>
  <condition>Alzheimer's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-Abeta</intervention_name>
    <description>Intravenous single and multiple doses</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Intravenous single and multiple doses</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of probable AD according to the NINCDS-ADRDA Criteria

          -  Approved AD treatments (AchE inhibitors+/-memantine) must be stable for ≥ 3 months
             prior to screening

          -  Other prescription medications must be stable for ≥ 1 month prior to screening

        Exclusion Criteria:

          -  Female patients with reproductive potential

          -  History or presence of any clinically significant CNS disease

          -  History of treatment with any protein therapeutic targeting Abeta
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>86 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carole Ho, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2008</study_first_submitted>
  <study_first_submitted_qc>August 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2008</study_first_posted>
  <last_update_submitted>October 26, 2010</last_update_submitted>
  <last_update_submitted_qc>October 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Disclosures Group</name_title>
    <organization>Genentech, Inc.</organization>
  </responsible_party>
  <keyword>AD</keyword>
  <keyword>Alzheimer's</keyword>
  <keyword>Alzheimers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

